MedscapeLIVE logo

Bispecific Antibodies for Treatment

A 3 Part Series

5:00 pm – 6:00 pm  TZ

Virtual
CME
swoosh
swoosh

Webinar 1: Hematology Half-Time Report: Overview of the Current Role of Bispecific Antibodies for Hematologic Malignancies

Tuesday, May 2, 2023, 1:30-2:00pm ET

In this first episode of 3, Dr Jacobson will provide foundational information about bispecifics including their mechanism of action and safety data.

 

Webinar 2: Hematology Half-Time Report: Bispecific Antibodies for the Treatment of Diffuse Large B-Cell Lymphoma

Thursday, May 25, 2023, 12:00-12:30pm ET

This is part 2 of a 3-part Webinar series on bispecific antibodies (BsAbs) being developed for various hematologic malignancies. Part 2 addresses novel BsAbs being explored in clinical trials for diffuse large B-cell lymphoma (DLBCL). Dr Matasar will explain how BsAbs work and review current data on their safety and efficacy. He will also discuss concerning treatment-related events of BsAbs and how to identify, prevent, and manage them. Finally, he will share his insights on how BsAbs might fit into the treatment paradigm for DLBCL. Dr Matasar will finish up by answering your questions about BsAbs for DLBCL.

 

Webinar 3: Hematology Half-Time Report: Bispecific Antibodies for the Treatment of Follicular Lymphoma

Monday, June 26, 2023, 1:00-1:30pm ET

This is part 3 of a 3-part Webinar series on bispecific antibodies (BsAbs) being developed for various hematologic malignancies. Part 3 addresses novel BsAbs being explored in clinical trials for follicular lymphoma (FL). Dr Gopal will explain how BsAbs work and review current data on their safety and efficacy. He will also discuss concerning treatment-related events of BsAbs and how to identify, prevent, and manage them. Finally, he will share his insights on how BsAbs might fit into the treatment paradigm for FL. Dr Gopal will finish up by answering your questions about BsAbs for FL.

 

TARGET AUDIENCE

Target Audience - Dolor sit amet consectetur adipiscing elit ut

GOAL STATEMENT

Goal Statement - Nibh venenatis cras sed felis eget. In cursus turpis massa tincidunt dui ut ornare.

LEARNING OBJECTIVES

Upon completion of this activity, participants will: Have increased knowledge regarding the [list][item]Learning objective one [item]Learning objective two [/list]Have greater competence related to: [list][item]Learning objective one [item]Learning objective two [/list]

ACCREDITATION STATEMENT

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

[bold]For Physicians[/bold] Medscape, LLC designates this live activity for a maximum of 1.0 [italic][bold]AMA PRA Category 1 Credit(s)™[/bold][/italic]. Physicians should claim only the credit commensurate with the extent of their participation in the activity. [bold]For Nurses[/bold] Medscape, LLC designates this live activity for a maximum [bold]For Physicians[/bold] Medscape, LLC designates this live activity for a maximum of 1.0 [italic][bold]AMA PRA Category 1 Credit(s)™[/bold][/italic]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

⌃